AIRLINK 177.00 Increased By ▲ 2.40 (1.37%)
BOP 12.81 Increased By ▲ 0.29 (2.32%)
CNERGY 7.49 Increased By ▲ 0.16 (2.18%)
FCCL 42.02 Increased By ▲ 2.09 (5.23%)
FFL 14.84 Increased By ▲ 0.16 (1.09%)
FLYNG 27.70 Decreased By ▼ -0.13 (-0.47%)
HUBC 134.51 Increased By ▲ 0.88 (0.66%)
HUMNL 12.96 Decreased By ▼ -0.01 (-0.08%)
KEL 4.44 Increased By ▲ 0.07 (1.6%)
KOSM 6.06 Increased By ▲ 0.05 (0.83%)
MLCF 54.51 Increased By ▲ 1.32 (2.48%)
OGDC 222.58 Increased By ▲ 9.67 (4.54%)
PACE 6.03 Increased By ▲ 0.03 (0.5%)
PAEL 41.30 Increased By ▲ 0.20 (0.49%)
PIAHCLA 15.62 Increased By ▲ 0.11 (0.71%)
PIBTL 10.06 Increased By ▲ 0.48 (5.01%)
POWER 11.17 Increased By ▲ 0.23 (2.1%)
PPL 183.99 Increased By ▲ 12.88 (7.53%)
PRL 34.31 Increased By ▲ 0.98 (2.94%)
PTC 23.34 Increased By ▲ 0.32 (1.39%)
SEARL 91.07 Decreased By ▼ -0.30 (-0.33%)
SILK 1.11 No Change ▼ 0.00 (0%)
SSGC 33.98 Increased By ▲ 1.47 (4.52%)
SYM 15.96 Decreased By ▼ -0.04 (-0.25%)
TELE 7.86 Decreased By ▼ -0.01 (-0.13%)
TPLP 11.01 Increased By ▲ 0.02 (0.18%)
TRG 58.72 Increased By ▲ 0.42 (0.72%)
WAVESAPP 10.79 Decreased By ▼ -0.30 (-2.71%)
WTL 1.36 Increased By ▲ 0.02 (1.49%)
YOUW 3.81 Increased By ▲ 0.02 (0.53%)
BR100 12,023 Increased By 222.2 (1.88%)
BR30 36,605 Increased By 1166.7 (3.29%)
KSE100 113,713 Increased By 1459.4 (1.3%)
KSE30 35,302 Increased By 517.9 (1.49%)

FRANKFURT: Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs such as psoriasis and arthritis drug Cosentyx.

In a statement on Tuesday, Novartis said it expects full-year core operating income, adjusted for one-off items, to grow by a “high teens” percentage, compared with a previous guidance of “mid- to high teens” percentage.

The group, which has cut jobs and spun off generic drugs business Sandoz to focus on new drug development, also posted better-than-expected third-quarter earnings, helped by revenue gains from anti-inflammation drug Cosentyx, among other factors.

Novartis aims for 5% annual sales growth through 2027

Quarterly adjusted core operating income gained 17% to $5.15 billion, beating an average analyst estimate of over $4.8 billion.

Quarterly Cosentyx sales gained 27% to $1.69 billion, helped by its recent approval to treat hidradenitis suppurativa, a painful acne-like skin condition.

Comments

200 characters